Association between Helicobacter pylori infection, mismatch repair, HER2 and tumor-infiltrating lymphocytes in gastric cancer

Table 1 Clinicopathological features and prognostic value

Feature	Total (n = 503)	%	Median	5 yr DFS	P value	Median	5 yr OS	P value
Age, yr (19-95 yr)
< 60	231	45.9	4.6	49.1	0.043	7.0	52.5	0.009
≥ 60	272	54.1	3.0	39.6		3.7	41.6
Sex
Female	252	50.1	3.3	43.7	0.582	3.8	45.3	0.319
Male	251	49.9	4.0	44.6		4.5	48.2
Bormann
I-II	90	18.1	NA	65.4	< 0.001	NA	66.0	0.002
III	311	62.7	2.9	40.6		4.0	44.4
IV-V	95	19.2	2.6	36.8		2.8	37.6
Lauren (n = 496)
Intestinal	222	44.8	4.3	39.9	0.716	4.8	49.3	0.598
Diffuse	181	36.5	3.0	46.2		4.1	43.9
Mixed	93	18.8	2.3	42.9		3.2	43.2
Grade
1	46	9.1	NA	62.2	0.025	NA	67.8	0.044
2	160	31.8	4.4	46.9		4.5	49.0
3	297	59.1	2.5	39.7		3.6	42.3
ILV
No	149	29.6	6.9	62.4	< 0.001	8.1	66.4	< 0.001
Yes	354	70.4	2.4	36.5		3.0	38.5
Antrum
Yes	323	64.2	2.7	47.9	0.064	3.5	51.0	0.104
No	180	35.8	4.5	38.8		5.1	40.8
Clinical stage
I	64	12.7	NA	80.7	< 0.001	NA	83.0	< 0.001
II	138	27.4	7.7	59.6		7.7	59.5
III	301	59.8	1.9	29.3		2.3	33.2
Node involvement
No	139	27.6	10.5	67.0	< 0.001	NA	68.2	< 0.001
Yes	364	72.4	2.3	35.4		3.0	38.4
Recurrence
No	322	64.0	-	-	-	NA	68.5	< 0.001
Yes	181	36.0	-	-		1.7	12.3
H. pylori HE (n = 415)
Absent	184	44.3	3.8	42.9	0.252	4.5	46.0	0.637
Present	231	55.7	7.3	48.3		5.3	51.2
H. pylori qPCR (n = 234)
Negative	85	36.3	2.5	36.8	0.229	3.1	39.1	0.219
Positive	149	63.7	3.8	38.3		4.0	39.7
dMMR (n = 479)
No	269	65.6	4.3	45.8	0.396	4.7	47.9	0.158
Yes	141	34.4	3.1	42.6	-	3.6	44.7	-
HER-2 status (n = 468)
Negative	434	95.0	3.5	43.4	0.868	4.3	46.2	0.892
Positive	23	5	3.1	39.8		3.3	39.3
IT TIL (n = 462)
< 10	186	40.3	2.7	41.8	0.763	3.7	43.6	0.395
≥ 10	276	59.7	3.7	44.0		4.5	47.1
ST TIL (n = 461)
< 30	258	55.9	2.6	41.5	0.458	3.8	45.0	0.853
≥ 30	203	44.0	3.8	44.8		4.4	46.3
IB TIL (n = 332)
< 70	178	53.6	3.3	46.0	0.991	4.4	47.8	0.660
≥ 70	154	46.4	4.4	46.4		4.9	49.4
IT CD3/HPF (n = 453)
< 58	126	27.8	2.4	34.3	0.028	2.9	36.5	0.021
≥ 58	327	72.2	4.4	47.0		5.4	50.5
IT CD8/ HPF (n = 443)
< 70	231	52.1	4.4	47.4	0.060	4.8	49.9	0.142
≥ 70	212	47.9	2.6	40.4		4.0	43.8
IT CD163/HPF (n = 205)
< 240	183	89.3	2.8	42.7	0.002	3.8	45.3	0.003
≥ 240	22	10.7	1.4	0.0		1.5	0.0
IT CD8/CD3 ratio (n = 432)
< 0.63	210	48.6	4.5	49.1	<0.001	6.0	52.9	0.001
≥ 0.63	222	51.4	2.3	36.0		2.8	38.5
IT CD3/CD163 (n = 179)
< 8	137	76.5	22	33.9	0.004	2.6	36.6	0.002
≥ 8	42	23.5	NA	59.5		NA	64.3
ST CD3/HPF (n = 363)
< 95	180	49.6	2.6	36.6	0.014	2.9	38.7	0.003
≥ 95	183	50.4	5.2	50.7		7.0	54.6
ST CD8/HPF (n = 341)
< 68	216	63.3	3.8	43.5	0.578	4.0	45.0	0.382
≥ 68	125	36.7	3.6	43.0		4.5	47.5
ST CD8/CD3 ratio (n = 328)
< 1.2	277	84.5	4.3	45.9	0.005	4.6	49.1	0.002
≥ 1.2	51	15.5	1.9	26.1		2.0	26.6

NA: Not available; HE: Hematoxylin and eosin; IT: Intratumoral; ST: Stromal; IB: Invasive border; TIL: Tumor-infiltrating lymphocytes; dMMR: Deficient mismatch-repair; H. pylori: Helicobacter pylori; HPF: High power field; DFS: Disease-free survival; OS: Overall survival; qPCR: Quantitative PCR.